Article
Discovery of D6808, a Highly Selective and Potent Macrocyclic c-Met Inhibitor for Gastric Cancer Harboring MET Gene Alteration Treatment.
Journal of medicinal chemistry - 24 Nov 2022
Wang Chaofan, Li Jie, Qu Lingzhi, Tang Xia, Song Xiaojuan, Yang Fang, Chen Xiaojuan, Lin Qianmeng, Lin Weibin, Zhou Yang, Tu ZhengChao, Chen Yongheng, Zhang Zhang, Lu Xiaoyun
Abstract excerpt
MET alterations have been validated as a driven factor in NSCLC and gastric cancers. The c-Met inhibitors, capmatinib, tepotinib, and savolitinib, are only approved for the treatment of NSCLC harboring exon 14 skipping mutant MET. We used a molecular hybridization in conjunction with macrocyclization strategy for structural optimization to obtain a series of 2-(2-(quinolin-6-yl)ethyl)pyridazin-3(2H)-one...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.